Cytori Therapeutics (CYTX)

Business description

Cytori sells the Celution device to harvest and concentrate adipose cells at the bedside for autologous therapy. It is CE marked. Two cardiac studies are underway in heart attack recovery and chronic heart disease.

Share price chart

Share chart

Stock data

Market cap.US$43.5m
Last closeUS$0.47
High / Low (52 weeks)US$3.3 / US$0.4
Stock market listingUS
Forecast net debt (US$m)31.8
Forecast gearing ratio (%)141
TeamHealthcare
SectorPharmaceutical & Healthcare

Price performance

%1m3m12m
Actual(4.7)(6.7)(82.1)
Relative *(1.5)(8.5)(84.3)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate AG
Aastrom Biosciences AB Science
Abcam Ablynx
Abzena Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Addex Therapeutics
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris Agennix
Alchemia Alexza Pharmaceuticals
Algeta ALK Abello
Alkermes Allergy Therapeutics
Alliance Pharma Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Animalcare Group Anteo Diagnostics
Anthera Pharmaceuticals Aratana Therapeutics
Ardea Biosciences Ardelyx
Arena Pharmaceuticals arGEN-X
Argos Therapeutics Ariad Pharmaceuticals
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Astex Pharmaceuticals Athersys
Avacta Group AVEO Pharmaceuticals
Avita Medical Balda
Basilea Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences Inv BioLineRx
Bionomics Bionor Pharma
Biota Holdings Biotie Therapies Corp
Biotron Bluebird Bio
BTG Can-Fite BioPharma
Capstone Therapeutics Cardio3 BioSciences
CARMAT Celldex Therapeutics
Cellectis Circadian Technologies
Clavis Pharma Cleveland BioLabs
Clinigen Clinuvel
Consort Medical Curis
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Delcath Systems Deltex Medical
Derma Sciences DiaSorin
Diaxonhit e-Therapeutics
EKF Diagnostics Emergent BioSolutions
Endocyte Epigenomics
Epistem Holdings Erytech Pharma
Esperion Therapeutics Evolva
Evotec Exact Sciences
Exelixis Formycon
Futura Medical Galapagos
Galmed Pharmaceuticals Genfit
Genmab GeoVax
GI Dynamics Gilead Sciences
GNI Group Ltd GW Pharmaceuticals
Halozyme Therapeutics Horizon Discovery
Hutchison China MediTech Hybrigenics
iCo Therapeutics Idenix
Immune Pharmaceuticals Immunodiagnostic Systems Holdings
ImmuPharma Imugene
Incyte Corporation Infinity Pharmaceuticals
Innate Pharma Insmed
Invion Ion Beam Applications
Ipsogen Ironwood Pharmaceuticals
Islet Sciences Ixico
KaloBios Pharmaceuticals Karolinska Development
Keryx Biopharmaceuticals LCA-Vision
LeMaitre Vascular Lifeline Scientific
Ligand Pharmaceuticals Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
Medigene Medivir
Merrimack Pharmaceuticals Merrion Pharmaceuticals
Mesoblast MethylGene
Midatech MolMed
Mologen AG MorphoSys
Nanobiotix Nanosonics
Nektar Therapeutics Neovacs
Newron Pharmaceuticals NicOx
NMC Health NorDiag
Nordion NovaBay Pharmaceuticals
Novogen NPS Pharmaceuticals
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals OPMEDIC Group
Optos Orexigen Therapeutics
Orexo Ossur
OvaScience Oxford BioMedica
Pacific Edge Paion
Paladin Labs Patheon
Pharmacyclics Pharmaxis
Pharming Group Photocure
Phylogica Prescient Therapeutics
Prima BioMed ProMetic Life Sciences
Prosensa Proteome Sciences
QRxPharma Quantum Pharmaceuticals
Regeneus ReNeuron Group
Resverlogix REVA Medical
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
SymBio Pharmaceuticals Synairgen
Synergy Health Synta Pharmaceuticals
Tekmira TESARO
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix
Tissue Therapies Topotarget
Transgene Trillium Therapeutics
Trimel Pharmaceuticals UCB
UDG Healthcare uniQure NV
Vectura Verastem
Verisante Technology Vernalis
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus WaferGen Biosystems
Wilex Xencor
Zafgen Zealand Pharma
Zeltia Ziopharm Oncology
Y/E Dec Revenue (US$m) EBITDA (US$m) PBT (US$m) EPS (c) P/E (x) P/CF (x)
2012A 14.5 (28.4) (33.0) (56.3) N/A N/A
2013A 12.2 (32.6) (38.1) (56.2) N/A N/A
2014E 12.4 (35.3) (40.2) (53.5) N/A N/A
2015E 33.3 (22.9) (27.0) (35.9) N/A N/A

Last updated on 09/12/2014

Investment summary

Cytori has gained a new $12m BARDA contract for a thermal burns indication for its patient-derived adipose- (fat) derived regenerative cells (ADRC). Any trial would gain a further $8.3m in support, making $20.4m in total. The ATHENA ischemic cardiomyopathy trial (40m and 80m cell dose arms) has restarted with data due in Q115. H114 revenues were $2.7m with $3.6m of sales due to be recognised in H214. Cash and equivalents on 30 June stood at $12.8m. Cytori raised $10m gross in June 2014.

Last updated on 22/12/2014

Industry outlook

Cardio3 (autologous) and Teva/Mesoblast (allogenic) both have Phase III studies in chronic ischemic heart disease under way. A 12-patient Scleroderma study reduced hand disability and pain. Promising results (20 patients) in a feasibility trial of in anterior cruciate ligament Repair have been reported. EU operations are being consolidated to a new office and manufacturing facility in Wales, UK. Cytori is well positioned to see faster progress on gaining therapeutic claims and reimbursement in Japan.

Last updated on 22/12/2014

Key management

Christopher Calhoun , CEO
Marc Hendrick, CEO
Mark Saad , CFO
Tiago Girao, CFO

Company address

3020 Callan Road
San Diago
CA 92121
United States
+1.858.458.0900
View website